Can Philips Expanded Deal Supercharge 4DMedicals Growth Story?
Source: Kapitales Research
Highlights:
4DMedical Limited (ASX: 4DX) gained attention after Koninklijke Philips expanded its global distribution agreement for the FDA-cleared CT:VQ lung imaging solution.
The move builds on September 2025 FDA clearance and CMS reimbursement, potentially accelerating hospital adoption through Philips’ worldwide imaging network.
While the deal strengthens the growth narrative, investors remain focused on 4DMedical’s short cash runway and reliance on future capital raises.
Global Distribution Boost Puts Spotlight on CT:VQ
4DMedical Limited (ASX: 4DX) has moved back into investor focus after imaging giant Koninklijke Philips announced an expansion of its distribution agreement for the company’s CT:VQ lung imaging technology. In early December 2025, Philips held a special call outlining plans to widen global access to the FDA-cleared, non-contrast CT:VQ ventilation and perfusion solution. At the time of writing, the development is being viewed as a potentially meaningful step toward accelerating hospital adoption worldwide.
Why the Philips Expansion Matters
The expanded agreement allows CT:VQ to tap into Philips’ extensive global imaging footprint, significantly broadening its commercial reach. For 4DMedical, this strengthens the pathway from regulatory approval to real-world clinical use. The move builds on a key milestone achieved in September 2025, when CT:VQ secured US FDA 510(k) clearance alongside CMS reimbursement, formally enabling both clinical use and payment in the world’s largest healthcare market.
With Philips now positioned to distribute the product more widely, the focus shifts to how quickly hospitals convert interest into routine, billable scans. That uptake rate will be crucial in determining whether revenue growth can scale fast enough.
Strong Growth Ambitions, Funding Questions Remain
At the time of writing, 4DMedical’s longer-term projections point to revenue of about AU$48.5 million and earnings of AU$17.4 million by 2028. Achieving those targets implies annual revenue growth of more than 100 per cent and a sharp turnaround from current losses. While the Philips deal reinforces the commercial opportunity, it does not eliminate concerns around cash runway and potential dilution from future capital raisings.
Valuation Views Remain Split
Investor opinions remain wide-ranging. Community-based valuation estimates span from as low as AU$0.19 to as high as AU$4.25 per share, highlighting uncertainty around execution risk. At the time of writing, some models suggest a fair value near AU$2.30, slightly below the current share price.
Disclaimer for Kapitales Research
The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to this. Read our Privacy Policy and Terms & Conditions
Can Philips Expanded Deal Supercharge 4DMedicals Growth Story?
Highlights:
Global Distribution Boost Puts Spotlight on CT:VQ
4DMedical Limited (ASX: 4DX) has moved back into investor focus after imaging giant Koninklijke Philips announced an expansion of its distribution agreement for the company’s CT:VQ lung imaging technology. In early December 2025, Philips held a special call outlining plans to widen global access to the FDA-cleared, non-contrast CT:VQ ventilation and perfusion solution. At the time of writing, the development is being viewed as a potentially meaningful step toward accelerating hospital adoption worldwide.
Why the Philips Expansion Matters
The expanded agreement allows CT:VQ to tap into Philips’ extensive global imaging footprint, significantly broadening its commercial reach. For 4DMedical, this strengthens the pathway from regulatory approval to real-world clinical use. The move builds on a key milestone achieved in September 2025, when CT:VQ secured US FDA 510(k) clearance alongside CMS reimbursement, formally enabling both clinical use and payment in the world’s largest healthcare market.
With Philips now positioned to distribute the product more widely, the focus shifts to how quickly hospitals convert interest into routine, billable scans. That uptake rate will be crucial in determining whether revenue growth can scale fast enough.
Strong Growth Ambitions, Funding Questions Remain
At the time of writing, 4DMedical’s longer-term projections point to revenue of about AU$48.5 million and earnings of AU$17.4 million by 2028. Achieving those targets implies annual revenue growth of more than 100 per cent and a sharp turnaround from current losses. While the Philips deal reinforces the commercial opportunity, it does not eliminate concerns around cash runway and potential dilution from future capital raisings.
Valuation Views Remain Split
Investor opinions remain wide-ranging. Community-based valuation estimates span from as low as AU$0.19 to as high as AU$4.25 per share, highlighting uncertainty around execution risk. At the time of writing, some models suggest a fair value near AU$2.30, slightly below the current share price.
Disclaimer for Kapitales Research
The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au